145 related articles for article (PubMed ID: 24691140)
1. Dynamic contrast-enhanced computed tomography as a potential biomarker in patients with metastatic renal cell carcinoma: preliminary results from the Danish Renal Cancer Group Study-1.
Mains JR; Donskov F; Pedersen EM; Madsen HH; Rasmussen F
Invest Radiol; 2014 Sep; 49(9):601-7. PubMed ID: 24691140
[TBL] [Abstract][Full Text] [Related]
2. Dynamic Contrast-Enhanced Computed Tomography-Derived Blood Volume and Blood Flow Correlate With Patient Outcome in Metastatic Renal Cell Carcinoma.
Mains JR; Donskov F; Pedersen EM; Madsen HH; Rasmussen F
Invest Radiol; 2017 Feb; 52(2):103-110. PubMed ID: 27513367
[TBL] [Abstract][Full Text] [Related]
3. The prognostic and predictive value of vascular response parameters measured by dynamic contrast-enhanced-CT, -MRI and -US in patients with metastatic renal cell carcinoma receiving sunitinib.
Hudson JM; Bailey C; Atri M; Stanisz G; Milot L; Williams R; Kiss A; Burns PN; Bjarnason GA
Eur Radiol; 2018 Jun; 28(6):2281-2290. PubMed ID: 29383520
[TBL] [Abstract][Full Text] [Related]
4. Prognostic value of DCE-CT-derived blood volume and flow compared to core biopsy microvessel density in patients with metastatic renal cell carcinoma.
Drljevic-Nielsen A; Rasmussen F; Nielsen PS; Stilling C; Thorup K; Mains JR; Madsen HHT; Donskov F
Eur Radiol Exp; 2021 Jul; 5(1):32. PubMed ID: 34327591
[TBL] [Abstract][Full Text] [Related]
5. Metastatic renal carcinoma: evaluation of antiangiogenic therapy with dynamic contrast-enhanced CT.
Fournier LS; Oudard S; Thiam R; Trinquart L; Banu E; Medioni J; Balvay D; Chatellier G; Frija G; Cuenod CA
Radiology; 2010 Aug; 256(2):511-8. PubMed ID: 20551183
[TBL] [Abstract][Full Text] [Related]
6. Dynamic contrast-enhanced CT-derived blood flow measurements enable early prediction of long term outcome in metastatic renal cell cancer patients on antiangiogenic treatment.
Spek A; Graser A; Casuscelli J; Szabados B; Rodler S; Marcon J; Stief C; Staehler M
Urol Oncol; 2022 Jan; 40(1):13.e1-13.e8. PubMed ID: 34535355
[TBL] [Abstract][Full Text] [Related]
7. Perfusion CT in patients with metastatic renal cell carcinoma treated with interferon.
Ng CS; Wang X; Faria SC; Lin E; Charnsangavej C; Tannir NM
AJR Am J Roentgenol; 2010 Jan; 194(1):166-71. PubMed ID: 20028919
[TBL] [Abstract][Full Text] [Related]
8. Tumour burden is an independent prognostic factor in metastatic renal cell carcinoma.
Iacovelli R; Lanoy E; Albiges L; Escudier B
BJU Int; 2012 Dec; 110(11):1747-53. PubMed ID: 23106948
[TBL] [Abstract][Full Text] [Related]
9. Utilizing pre-therapy clinical schema and initial CT changes to predict progression-free survival in patients with metastatic renal cell carcinoma on VEGF-targeted therapy: a preliminary analysis.
Smith AD; Shah SN; Rini BI; Lieber ML; Remer EM
Urol Oncol; 2013 Oct; 31(7):1283-91. PubMed ID: 21956044
[TBL] [Abstract][Full Text] [Related]
10. Angiogenesis of renal cell carcinoma: perfusion CT findings.
Chen Y; Zhang J; Dai J; Feng X; Lu H; Zhou C
Abdom Imaging; 2010 Oct; 35(5):622-8. PubMed ID: 19763683
[TBL] [Abstract][Full Text] [Related]
11. Computed tomography perfusion imaging of renal cell carcinoma: systematic comparison with histopathological angiogenic and prognostic markers.
Reiner CS; Roessle M; Thiesler T; Eberli D; Klotz E; Frauenfelder T; Sulser T; Moch H; Alkadhi H
Invest Radiol; 2013 Apr; 48(4):183-91. PubMed ID: 23328912
[TBL] [Abstract][Full Text] [Related]
12. Dynamic contrast-enhanced magnetic resonance imaging in the early evaluation of anti-angiogenic therapy in metastatic renal cell carcinoma.
Panebianco V; Iacovelli R; Barchetti F; Altavilla A; Forte V; Sciarra A; Cortesi E; Catalano C
Anticancer Res; 2013 Dec; 33(12):5663-6. PubMed ID: 24324114
[TBL] [Abstract][Full Text] [Related]
13. Alternative Response Criteria and Clinical Risk Factors for Assessing Tumor Response in Patients With Metastatic Renal Cell Carcinoma Who Are Receiving Salvage Therapy.
Kang HC; Gupta S; Wei W; Lu L; Matrana MR; Tannir NM; Choi H
AJR Am J Roentgenol; 2017 Dec; 209(6):1278-1284. PubMed ID: 29064751
[TBL] [Abstract][Full Text] [Related]
14. Cytoreductive radiofrequency ablation in patients with metastatic renal cell carcinoma (RCC) with small primary tumours treated with sunitinib or interferon-α.
Tsimafeyeu I; Zart JS; Chung B
BJU Int; 2013 Jul; 112(1):32-8. PubMed ID: 23746142
[TBL] [Abstract][Full Text] [Related]
15. CT quantification of effects of thalidomide in patients with metastatic renal cell carcinoma.
Faria SC; Ng CS; Hess KR; Phongkitkarun S; Szejnfeld J; Daliani D; Charnsangavej C
AJR Am J Roentgenol; 2007 Aug; 189(2):378-85. PubMed ID: 17646464
[TBL] [Abstract][Full Text] [Related]
16. Skeletal muscle density predicts prognosis in patients with metastatic renal cell carcinoma treated with targeted therapies.
Antoun S; Lanoy E; Iacovelli R; Albiges-Sauvin L; Loriot Y; Merad-Taoufik M; Fizazi K; di Palma M; Baracos VE; Escudier B
Cancer; 2013 Sep; 119(18):3377-84. PubMed ID: 23801109
[TBL] [Abstract][Full Text] [Related]
17. Comparison of four early posttherapy imaging changes (EPTIC; RECIST 1.0, tumor shrinkage, computed tomography tumor density, Choi criteria) in assessing outcome to vascular endothelial growth factor-targeted therapy in patients with advanced renal cell carcinoma.
Krajewski KM; Guo M; Van den Abbeele AD; Yap J; Ramaiya N; Jagannathan J; Heng DY; Atkins MB; McDermott DF; Schutz FA; Pedrosa I; Choueiri TK
Eur Urol; 2011 May; 59(5):856-62. PubMed ID: 21306819
[TBL] [Abstract][Full Text] [Related]
18. Dynamic contrast-enhanced magnetic resonance imaging pharmacodynamic biomarker study of sorafenib in metastatic renal carcinoma.
Hahn OM; Yang C; Medved M; Karczmar G; Kistner E; Karrison T; Manchen E; Mitchell M; Ratain MJ; Stadler WM
J Clin Oncol; 2008 Oct; 26(28):4572-8. PubMed ID: 18824708
[TBL] [Abstract][Full Text] [Related]
19. Diffusion weighted and dynamic contrast enhanced MRI as an imaging biomarker for stereotactic ablative body radiotherapy (SABR) of primary renal cell carcinoma.
Reynolds HM; Parameswaran BK; Finnegan ME; Roettger D; Lau E; Kron T; Shaw M; Chander S; Siva S
PLoS One; 2018; 13(8):e0202387. PubMed ID: 30114235
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of response to multikinase inhibitor in metastatic renal cell carcinoma by FDG PET/contrast-enhanced CT.
Minamimoto R; Nakaigawa N; Tateishi U; Suzuki A; Shizukuishi K; Kishida T; Miura T; Makiyama K; Yao M; Kubota Y; Inoue T
Clin Nucl Med; 2010 Dec; 35(12):918-23. PubMed ID: 21206220
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
